# Adherence and Safety of Ribociclib Plus Aromatase Inhibitors in Patients With Early Stage, HR+ and HER2- Breast Cancer

> **NCT07630948** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Institute of Oncology Ljubljana** · enrollment: 90 (estimated)

## Conditions studied

- Breast Cancer
- Adherence, Medication

## Interventions

- **BEHAVIORAL:** Adherence package consisting of additional education and adherence reminders

## Key facts

- **NCT ID:** NCT07630948
- **Lead sponsor:** Institute of Oncology Ljubljana
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2029-09-01
- **Final completion:** 2032-09-01
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07630948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07630948, "Adherence and Safety of Ribociclib Plus Aromatase Inhibitors in Patients With Early Stage, HR+ and HER2- Breast Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07630948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*